Global health care company Abbott Laboratories has initiated a medical device correction on nearly 3 million glucose-monitoring sensors following internal testing that indicated some sensors may provide incorrect low glucose readings.
The device corrections include the FreeStyle Libre 3 and FreeStyle Libre 3 Plus models in the United States. The FreeStyle Libre 3 system is a continuous glucose-monitoring (CGM) system that includes the sensor and a Libre app. The sensor is typically applied to the back of the patient’s upper arm and automatically streams glucose readings to a smartphone.
